Compare BTDR & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | PTCT |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | BTDR | PTCT |
|---|---|---|
| Price | $10.97 | $78.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 17 |
| Target Price | $28.30 | ★ $73.76 |
| AVG Volume (30 Days) | ★ 6.7M | 2.3M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 8.94 |
| Revenue | $464,436,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $73.71 | $128.32 |
| Revenue Next Year | $92.06 | N/A |
| P/E Ratio | ★ N/A | $8.79 |
| Revenue Growth | 17.40 | ★ 97.54 |
| 52 Week Low | $6.84 | $35.95 |
| 52 Week High | $27.80 | $87.50 |
| Indicator | BTDR | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 57.21 |
| Support Level | $9.66 | $73.78 |
| Resistance Level | $10.49 | $76.17 |
| Average True Range (ATR) | 0.80 | 2.73 |
| MACD | 0.13 | -0.49 |
| Stochastic Oscillator | 34.70 | 68.52 |
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.